18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 13, 2015, Pages 2021-2028

  Yu, Chunjing ^a   Pan, Donghui ^b   Mi, Baoming ^a   Xu, Yuping ^b   Lang, Lixin ^c   Niu, Gang ^c   Yang, Min ^b   Wan, Weixing ^a   Chen, Xiaoyuan ^c  

^a JIANGNAN UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Alfatide II; Brain metastasis; Integrin; PET CT; RGD peptide

Indexed keywords

ALFATIDE II F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ALFATIDE II; CYCLOPEPTIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DOSIMETRY; EFFECTIVE DOSE (RADIATION); FEMALE; HUMAN; IMAGE ANALYSIS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-CT SCANNER; PLASMA CLEARANCE; RADIOACTIVITY; RENAL CLEARANCE; BRAIN; BRAIN TUMOR; DIAGNOSTIC IMAGING; KIDNEY; MULTIMODAL IMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; SECONDARY; SPLEEN; TISSUE DISTRIBUTION; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; KIDNEY; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SPLEEN; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84945485618     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3118-2     Document Type: Article

References (34)

1. Cai H, Conti PS. RGD-based PET tracers for imaging receptor integrin αvβ3 expression. J Label Compd Radiopharm. 2013;56:264–79.
2. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011;1:30–47.
3. Gaertner FC, Schwaiger M, Beer AJ. Molecular imaging of αvβ3 expression in cancer patients. Q J Nucl Med Mol Imaging. 2010;54:309–26.
4. 18F-labeled monomeric and dimeric RGD peptides using compartment model. Mol Imaging Biol. 2012;14:743–52.
5. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179–89.
6. 2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol. 2012;39:377–87.
7. 18F]fluoroethylcholine. Curr Cancer Drug Targets. 2014;14:371–9.
8. 89Zr-RGD peptides. Mol Imaging Biol. 2011;13:1224–33.
9. 18F]galacto-RGD positron emission tomography for imaging of αvβ3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610–6.
10. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879–86.
11. 68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415–22.
12. 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.
13. Edman P. Method for determination of the amino acid sequence in peptides. Acta Chem Scand. 1950;4:283–93.
14. Lang L, Ma Y, Kiesewetter DO, Chen X. Stability analysis of glutamic acid linked peptides coupled to NOTA through different chemical linkages. Mol Pharm. 2014;11:3867–74.
15. 18F-Alfatide II and differentiation with tumors. Theranostics. 2014;4:546–55.
16. 18F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy. J Nucl Med. 2014;55:154–60.
17. Lassmann M, Chiesa C, Flux G, Bardies M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192–200.
18. 68Ga bombesin antagonist BAY 86–7548 in healthy men. J Nucl Med. 2013;54:867–72.
19. 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging αvβ3 integrin levels. Radiology. 2011;260:182–91.
20. Beer AJ, Schwaiger M. PET imaging of αvβ3 expression in cancer patients. Methods Mol Biol. 2011;680:183–200.
21. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.
22. 18F-FPPRGD2 PET/CT. Radiology. 2015 May 12. [Epub ahead of print].
23. 68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415–22.
24. 18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med. 2006;47:763–9.
25. 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53:787–95.
26. 18F-AH111585 in healthy volunteers. J Nucl Med. 2008;49:1664–7.
27. 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54:691–8.
28. 99mTc-3P4-RGD2 scintigraphy. Eur J Nucl Med Mol Imaging. 2011;38:2145–52.
29. 18F-FDG. J Nucl Med. 2008;49:22–9.
30. Peet AC, Arvanitis TN, Leach MO, Waldman AD. Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol. 2012;9:700–11.
31. Gulyas B, Halldin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging. 2012;56:173–90.
32. 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors. Nucl Med Biol. 2013;40:788–94.
33. 64Cu labeling and PET imaging of brain tumor αvβ3-integrin expression. J Nucl Med. 2004;45:1776–83.
34. Zadeh G, Guha A. Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors (review). Int J Oncol. 2003;23:557–65.